No clear pattern was observed in annual non-COPD hospitalisation rates between GOLD A, B, C and D severity categories, showing that patients were likely similar in their other comorbid condition severity.
Patient Population and Study Period
Patients registered in a CPRD practice linked to HES, with a diagnosis of COPD identified through Read codes anytime in their medical record up to the crosssectional date of 1 January 2011 were included.
Patients were excluded if they were < 40 years old at the time of diagnosis.
Patients were included in the study prevalent cohort if they were active on 1 January 2011 (index date) and had a minimum of 12 months of active data recording history prior to cohort entry.
Patients were classified into GOLD 2013 4 severity groups at index date using records of spirometry and dyspnea assessment available in CPRD and exacerbations defined using information from both primary and secondary care recorded in the 12 months prior.
Outcomes
The main outcomes in this study were assessed from index date until end of follow-up (the earliest of death, transfer out or end of study [December 2013] ).
Exacerbations
Episodes that occurred within a 21-day time period 5 were identified in both primary and secondary care settings by the following:
In primary care:
-A Read code in the clinical record indicating exacerbations or emergency admission to hospital due to COPD -An oral corticosteroid (OCS) and oral antibiotic (OAB) prescription occurring on the same date, with the OCS not being used as maintenance treatment -An OCS or OAB prescription that is not part of a maintenance episode occurring on the same date as a specific list of Read codes indicating exacerbations
In secondary care, exacerbations were defined as a hospitalisation recorded in the HES data with the International Classification of Diseases, Revision 10 (ICD-10) code J44.1 "Chronic obstructive pulmonary disease with acute exacerbation, unspecified" within the reasons for admission.
Resource Use
Resource use in primary care included general practitioner (GP) visits (at the surgery, home and telephone consultations).
Hospitalisations were captured in HES. COPD-related admissions were defined as admissions with at least one diagnosis related to COPD identified through ICD-10 codes (J40.X-J44.X, J47.X-J48.X). All other hospitalisations were classified as non-COPD.
Statistical Analyses
Patient demographics and clinical characteristics, including comorbid conditions and COPD medication, were summarised using descriptive statistics at 1 January 2011 using data from the 12 months prior (baseline period) as necessary; chronic comorbid conditions were assessed using all available records.
Incidence rates of COPD exacerbations (per person-year [PY]) and 95% confidence intervals (CIs) based on the Poisson approximation were calculated by the number of PYs among the overall COPD cohort over the same period.
Annual incidence rates of exacerbations and resource use in terms of COPDrelated and non-COPD-related hospitalisations, as well as GP visits, were calculated using the same formula as above for years 2011, 2012 and 2013.
All analyses were conducted using SAS software version 9.4 or STATA software version 11.
A total of 44,201 patients with COPD fulfilled the criteria for includsion in the study cohort.
Exacerbations of chronic obstructive pulmonary disease (COPD) contribute to the overall disease severity, and can be an important cause of hospital admission. 1 Health care resource use associated with the management of COPD in primary and secondary care results in a substantial economic burden borne by national health care systems. 2 In the United Kingdom (UK), COPD is the most common respiratory condition, with an estimated prevalence of 33 cases per 1,000 persons in 2013.
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STRENGTHS AND LIMITATIONS
A major strength of the present study was the use of a large database representative of the UK population and the inclusion of secondary care data from HES. This helped us improve existing methodology for defining exacerbations in the absence of a standardised way of recording these 3,4,6-8 by combining prescriptions and diagnosis records in primary care with records of hospital admission in the secondary care setting.
The lack of complete modified Medical Research Council records for dyspnea assessment did not allow the classification of all patients with COPD into the GOLD 2013 severity categories. Nevertheless, only 17% of patients remained unclassified, and these were found to be comparable in terms of their demographic and clinical characteristics.
Patients were not reclassified by GOLD criteria throughout the course of the study which may impact results, especially at later timepoints. However, based on estimates of disease progression it is unlikely that many patients will have transitioned between GOLD classes over the course of the study. In addition to a year over year increase in exacerbations across severity levels, GP interactions decreased with time indicating a possible shift of patient care from primary to secondary, reflecting the overall progressive nature of the disease.
Our findings suggest that better disease management that stabilises disease progression would potentially allow for an improvement in patients' quality of life and a reduction in health care resource utilisation.
GP Visits
The annual rates of GP visits were found to increase with disease severity from GOLD A to GOLD D: GOLD A: 4. 
Resource Use
COPD-related Hospital Admissions
The annual rates of COPD-related hospitalisations significantly increased from 2011 to 2013 regardless of severity of COPD (Figure 2 ).
The annual rates of COPD-related hospital admissions were highest among patients with higher disease symptoms categorised as GOLD A total of 17% of patients were unclassified due to incomplete records for dyspnea assessment: mean age at index was 71.4 years, 53.4% were females, and no significant differences in comorbidities were observed compared to GOLD classified patients.
COPD Medication Use
The use of reliever monotherapy was highest among patients in GOLD A: 15.8% of patients on short-acting beta agonists (SABA).
The majority of patients in the most severe GOLD D category were on a combination therapy (74.6%); the most frequent combination was long-acting beta agonists (LABA) + long-acting anticholinergics (LAMA) + inhaled corticosteriods (ICS) (29.9%).
A total of 22.8% of patients in GOLD A were not on any maintenance medication in the six months prior to index (1 January 2011), compared to only 3.7% in the most severe GOLD D category.
Epidemiology of COPD Exacerbations
The overall exacerbation rate for all patients for the total follow-up (2011-2013) was 1.4 exacerbations per PY (95% CI: 1.4-1.5).
Exacerbation rates increased with GOLD severity and over time with a year over year increase across all GOLD categories (Table 2, Figure 1 ).
